Literature DB >> 21470145

Tumor vasculature targeting through NGR peptide-based drug delivery systems.

Angelo Corti1, Flavio Curnis.   

Abstract

Various peptide sequences have been discovered by selecting peptide-phage display libraries in vitro against specific receptors or in vivo in tumor-bearing animals. One class of these peptides is characterized by the presence of Asn-Gly-Asp (NGR), a structural motif that can recognize the endothelium and other cells of neoangiogenic vessels. Because of this property these peptides have been used by several investigators to deliver a variety of drugs, cytokines, nanoparticles, viruses and imaging agents to tumor blood vessels. Here we review the reports on these conjugates and discuss the structural, functional and stability properties of NGR embedded into different molecular scaffolds.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21470145     DOI: 10.2174/138920111796117373

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  23 in total

Review 1.  Tumor vascular infarction: prospects and challenges.

Authors:  Rana Jahanban-Esfahlan; Khaled Seidi; Nosratollah Zarghami
Journal:  Int J Hematol       Date:  2017-01-02       Impact factor: 2.490

Review 2.  Chromogranin A and derived peptides in health and disease.

Authors:  Y Peng Loh; Yong Cheng; Sushil K Mahata; Angelo Corti; Bruno Tota
Journal:  J Mol Neurosci       Date:  2012-03-03       Impact factor: 3.444

3.  Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.

Authors:  Zheng-Hong Peng; Jindřich Kopeček
Journal:  J Am Chem Soc       Date:  2015-05-19       Impact factor: 15.419

Review 4.  Peptides as targeting elements and tissue penetration devices for nanoparticles.

Authors:  Erkki Ruoslahti
Journal:  Adv Mater       Date:  2012-05-02       Impact factor: 30.849

5.  Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.

Authors:  Si Wang; William J Placzek; John L Stebbins; Sayantan Mitra; Roberta Noberini; Mitchell Koolpe; Ziming Zhang; Russell Dahl; Elena B Pasquale; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2012-02-27       Impact factor: 7.446

6.  De novo design of a tumor-penetrating peptide.

Authors:  Luca Alberici; Lise Roth; Kazuki N Sugahara; Lilach Agemy; Venkata R Kotamraju; Tambet Teesalu; Claudio Bordignon; Catia Traversari; Gian-Paolo Rizzardi; Erkki Ruoslahti
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

7.  Targeted delivery of paclitaxel to EphA2-expressing cancer cells.

Authors:  Si Wang; Roberta Noberini; John L Stebbins; Swadesh Das; Ziming Zhang; Bainan Wu; Sayantan Mitra; Sandrine Billet; Ana Fernandez; Neil A Bhowmick; Shinichi Kitada; Elena B Pasquale; Paul B Fisher; Maurizio Pellecchia
Journal:  Clin Cancer Res       Date:  2012-11-15       Impact factor: 12.531

8.  Development of NGR peptide-based agents for tumor imaging.

Authors:  Rongsheng E Wang; Youhong Niu; Haifan Wu; Mohamad Nassir Amin; Jianfeng Cai
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-07-03

9.  68Ga-Chelation and comparative evaluation of N,N'-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid (HBED-CC) conjugated NGR and RGD peptides as tumor targeted molecular imaging probes.

Authors:  Drishty Satpati; Rohit Sharma; Chandan Kumar; Haladhar Dev Sarma; Ashutosh Dash
Journal:  Medchemcomm       Date:  2017-02-16       Impact factor: 3.597

10.  Glycine N-methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing.

Authors:  Angelo Corti; Anna Maria Gasparri; Michela Ghitti; Angelina Sacchi; Francesco Sudati; Martina Fiocchi; Valentina Buttiglione; Laura Perani; Alessandro Gori; Silvia Valtorta; Rosa Maria Moresco; Fabio Pastorino; Mirco Ponzoni; Giovanna Musco; Flavio Curnis
Journal:  Adv Funct Mater       Date:  2017-09-26       Impact factor: 18.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.